Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $18.56 to $19.21
• 50-Day Range: $12.53 to $18.97
• 52-Week Range: $8.89 to $24.50
• Volume: 313,407 shs
• Average Volume: 658,119 shs
• Market Capitalization: $813.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.56
• Consensus Rating: Moderate Buy

Beta Bionics Stock Analysis - MarketRank™

Beta Bionics scored higher than 37% of companies evaluated by MarketBeat, and ranked 807th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beta Bionics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Beta Bionics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BBNX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beta Bionics does not currently pay a dividend.

Dividend Growth

Beta Bionics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BBNX.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.13

News Sentiment

Beta Bionics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Beta Bionics this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,441.00 in company stock.

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the beginning of the year. Since then, BBNX stock has decreased by 21.4% and is now trading at $18.71.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) announced its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.12. The company earned $23.24 million during the quarter, compared to the consensus estimate of $19.73 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share.

When did Beta Bionics' lock-up period expire?

Beta Bionics's lock-up period expired on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Since the end of Beta Bionics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Beta Bionics' major shareholders?

Top institutional investors of Beta Bionics include Eventide Asset Management LLC (11.35%), Soleus Capital Management L.P. (8.79%), Sands Capital Alternatives LLC (8.21%) and Divisadero Street Capital Management LP (2.18%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Beta Bionics: $22.56
• High Price Target: $30.00
• Low Price Target: $16.00
• Potential Upside/Downside: +20.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.68
• Quick Ratio: 13.79

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 12.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.94 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 43,470,000
• Free Float: N/A
• Market Cap: $816.80 million
• Optionable: N/A
• Beta: N/A